211 related articles for article (PubMed ID: 9883220)
1. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma.
Giannakopoulos S; Gekas A; Alivizatos G; Sofras F; Becopoulos T; Dimopoulos C
Br J Urol; 1998 Dec; 82(6):829-34. PubMed ID: 9883220
[TBL] [Abstract][Full Text] [Related]
2. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group.
Raitanen MP; Lukkarinen O
Br J Urol; 1995 Dec; 76(6):697-701. PubMed ID: 8535711
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study.
Papatsoris AG; Deliveliotis C; Giannopoulos A; Dimopoulos C
Urol Int; 2004; 72(4):284-91. PubMed ID: 15153724
[TBL] [Abstract][Full Text] [Related]
4. [Clinical trial with intravesical alfa-2b interferon for the prevention of T1 transitional carcinoma of the bladder: preliminary results. Review of the bibliography].
Portillo Martín JA; Martín García B; Hernández Rodríguez R; Correas Gómez MA; Gutiérrez Baños JL; del Valle Schaan JI; Monge Mirallas JM; Roca Edreira A
Arch Esp Urol; 1995 Jun; 48(5):479-88. PubMed ID: 7639570
[TBL] [Abstract][Full Text] [Related]
5. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer.
Moltó L; Alvarez-Mon M; Carballido J; Olivier C; Gimeno F; Manzano L
Cancer; 1995 Jun; 75(11):2720-6. PubMed ID: 7743476
[TBL] [Abstract][Full Text] [Related]
6. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
8. Intravesical immunotherapy for superficial bladder cancer.
Said MT; Abomelha MS; Orkubi SA
Saudi Med J; 2002 Dec; 23(12):1458-61. PubMed ID: 12518191
[TBL] [Abstract][Full Text] [Related]
9. Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder.
Portillo J; Martin B; Hernandez R; Correas M; Gutierrez J; Del Valle J; Roca A; Vega A; Villanueva A; Gutierrez R
Urology; 1997 Feb; 49(2):187-90. PubMed ID: 9037279
[TBL] [Abstract][Full Text] [Related]
10. Interferon-a2b reduces neo-microvascular density in the 'normal' urothelium adjacent to the tumor after transurethral resection of superficial bladder carcinoma.
Giannopoulos A; Adamakis I; Evangelou K; Giannopoulou M; Zacharatos P; Zsantoulis P; Perunovic B; Athanasiou A; Retalis G; Constandinidis C; Gorgoulis VG
Onkologie; 2003 Apr; 26(2):147-52. PubMed ID: 12771523
[TBL] [Abstract][Full Text] [Related]
11. Ultrastructural study of the noninvolved urothelium of tumor-bearing patients after two years of intravesical interferon therapy.
Stravoravdi P; Natsis K; Kirtsis P; Retalis G; Konstandinidis E; Polyzonis M
Eur Urol; 1996; 29(4):477-82. PubMed ID: 8791058
[TBL] [Abstract][Full Text] [Related]
12. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha.
Jimenez-Cruz JF; Vera-Donoso CD; Leiva O; Pamplona M; Rioja-Sanz LA; Martinez-Lasierra M; Flores N; Unda M
Urology; 1997 Oct; 50(4):529-35. PubMed ID: 9338727
[TBL] [Abstract][Full Text] [Related]
13. Role of interferon-alpha-2b in the prevention of superficial carcinoma of the bladder recurrence.
Mohanty NK; Gulati P; Saxena S
Urol Int; 1997; 59(3):194-6. PubMed ID: 9428441
[TBL] [Abstract][Full Text] [Related]
14. A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder.
Malmström PU
BJU Int; 2002 May; 89(7):681-6. PubMed ID: 11966624
[TBL] [Abstract][Full Text] [Related]
15. Co-administration of intravesical bacillus Calmette-Guérin and interferon α-2B as first line in treating superficial transitional cell carcinoma of the urinary bladder.
Bazarbashi S; Soudy H; Abdelsalam M; Al-Jubran A; Akhtar S; Memon M; Aslam M; Kattan S; Shoukri M
BJU Int; 2011 Oct; 108(7):1115-8. PubMed ID: 21332904
[TBL] [Abstract][Full Text] [Related]
16. How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer?
Hoeltl W; Hasun R; Albrecht W; Marberger M
Br J Urol; 1991 Nov; 68(5):495-8. PubMed ID: 1747725
[TBL] [Abstract][Full Text] [Related]
17. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of superficial transitional cell bladder carcinoma. Long-term results of trial comparing transurethral resection alone and adjuvant chemotherapy with Doxorubicin].
Milonas D; Mickevicius J; Mickevicius R; Motiejūnas A; Sukys D; Gudinaviciene I
Medicina (Kaunas); 2002; 38 Suppl 1():79-83. PubMed ID: 12556642
[TBL] [Abstract][Full Text] [Related]
19. Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-alpha 2b versus interferon-alpha 2b with epirubicin.
Ferrari P; Castagnetti G; Pollastri CA; Ferrari G; Tavoni F; Grassi D
Anticancer Drugs; 1992 May; 3 Suppl 1():25-7. PubMed ID: 1611113
[TBL] [Abstract][Full Text] [Related]
20. Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.
Lam JS; Benson MC; O'Donnell MA; Sawczuk A; Gavazzi A; Wechsler MH; Sawczuk IS
Urol Oncol; 2003; 21(5):354-60. PubMed ID: 14670544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
